Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Rashmi Chugh

Showing results (91-100 of 123) with videos related to

Pageof 13
Sort By:
Cancer|April 30, 2019
A phase 1 and randomized controlled phase 2 trial of the safety and efficacy of the combination of gemcitabine and docetaxel with ontuxizumab (MORAb-004) in metastatic soft-tissue sarcomasRobin L Jones, Sant P Chawla, Steven Attia, et al.
Cancer|August 25, 2024
Consensus recommendations for systemic therapies in the management of relapsed Ewing sarcoma: A report from the National Ewing Sarcoma Tumor BoardAjay Gupta, Matthew S Dietz, Richard F Riedel, et al.
Nature Communications|March 26, 2026
Tazemetostat, an EZH2 inhibitor, in solid tumors harboring SWI/SNF alterations: a phase II basket studyMrinal Gounder, Patrick Schöffski, Robin L Jones, et al.
Journal for Immunotherapy of Cancer|August 12, 2021
Multicenter phase II trial (SWOG S1609, cohort 51) of ipilimumab and nivolumab in metastatic or unresectable angiosarcoma: a substudy of dual anti-CTLA-4 and anti-PD-1 blockade in rare tumors (DART)Michael J Wagner, Megan Othus, Sandip P Patel, et al.
Future Oncology (London, England)|December 22, 2025
A plain language summary of the AMPECT study: nab-sirolimus for advanced malignant perivascular epithelioid cell tumorsAndrew J Wagner, Vinod Ravi, Richard F Riedel, et al.
Cancer|December 29, 2015
SARC009: Phase 2 study of dasatinib in patients with previously treated, high-grade, advanced sarcomaScott M Schuetze, J Kyle Wathen, David R Lucas, et al.
Cancer|December 9, 2020
Real-world outcomes of patients with locally advanced or metastatic epithelioid sarcomaMrinal M Gounder, Priscilla Merriam, Ravin Ratan, et al.
JAMA Oncology|May 1, 2018
Association of Dasatinib With Progression-Free Survival Among Patients With Advanced Gastrointestinal Stromal Tumors Resistant to ImatinibScott M Schuetze, Vanessa Bolejack, Dafydd G Thomas, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|October 26, 2011
R1507, a monoclonal antibody to the insulin-like growth factor 1 receptor, in patients with recurrent or refractory Ewing sarcoma family of tumors: results of a phase II Sarcoma Alliance for Research through Collaboration studyAlberto S Pappo, Shreyaskumar R Patel, John Crowley, et al.
JCO Oncology Advances|May 7, 2025
Phase II Study of Pexidartinib Plus Sirolimus in Unresectable Malignant Peripheral Nerve Sheath Tumors Identifies M2 Macrophage ActivationGulam A Manji, Liam J Stanton, Angela C Hirbe, et al.
Pageof 13

Showing results (91-100 of 123) with videos related to

Sort By:
Pageof 13
Cancer|April 30, 2019
A phase 1 and randomized controlled phase 2 trial of the safety and efficacy of the combination of gemcitabine and docetaxel with ontuxizumab (MORAb-004) in metastatic soft-tissue sarcomasRobin L Jones, Sant P Chawla, Steven Attia, et al.
Cancer|August 25, 2024
Consensus recommendations for systemic therapies in the management of relapsed Ewing sarcoma: A report from the National Ewing Sarcoma Tumor BoardAjay Gupta, Matthew S Dietz, Richard F Riedel, et al.
Nature Communications|March 26, 2026
Tazemetostat, an EZH2 inhibitor, in solid tumors harboring SWI/SNF alterations: a phase II basket studyMrinal Gounder, Patrick Schöffski, Robin L Jones, et al.
Journal for Immunotherapy of Cancer|August 12, 2021
Multicenter phase II trial (SWOG S1609, cohort 51) of ipilimumab and nivolumab in metastatic or unresectable angiosarcoma: a substudy of dual anti-CTLA-4 and anti-PD-1 blockade in rare tumors (DART)Michael J Wagner, Megan Othus, Sandip P Patel, et al.
Future Oncology (London, England)|December 22, 2025
A plain language summary of the AMPECT study: nab-sirolimus for advanced malignant perivascular epithelioid cell tumorsAndrew J Wagner, Vinod Ravi, Richard F Riedel, et al.
Cancer|December 29, 2015
SARC009: Phase 2 study of dasatinib in patients with previously treated, high-grade, advanced sarcomaScott M Schuetze, J Kyle Wathen, David R Lucas, et al.
Cancer|December 9, 2020
Real-world outcomes of patients with locally advanced or metastatic epithelioid sarcomaMrinal M Gounder, Priscilla Merriam, Ravin Ratan, et al.
JAMA Oncology|May 1, 2018
Association of Dasatinib With Progression-Free Survival Among Patients With Advanced Gastrointestinal Stromal Tumors Resistant to ImatinibScott M Schuetze, Vanessa Bolejack, Dafydd G Thomas, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|October 26, 2011
R1507, a monoclonal antibody to the insulin-like growth factor 1 receptor, in patients with recurrent or refractory Ewing sarcoma family of tumors: results of a phase II Sarcoma Alliance for Research through Collaboration studyAlberto S Pappo, Shreyaskumar R Patel, John Crowley, et al.
JCO Oncology Advances|May 7, 2025
Phase II Study of Pexidartinib Plus Sirolimus in Unresectable Malignant Peripheral Nerve Sheath Tumors Identifies M2 Macrophage ActivationGulam A Manji, Liam J Stanton, Angela C Hirbe, et al.
Pageof 13